1. ChangY, CesarmanE, PessinMS, LeeF, CulpepperJ, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865–1869.
2. HenggeUR, RuzickaT, TyringSK, StuschkeM, RoggendorfM, et al. (2002) Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2: 281–292.
3. HenggeUR, RuzickaT, TyringSK, StuschkeM, RoggendorfM, et al. (2002) Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2: 344–352.
4. ChungYH, MeansRE, ChoiJK, LeeBS, JungJU (2002) Kaposi's sarcoma-associated herpesvirus OX2 glycoprotein activates myeloid-lineage cells to induce inflammatory cytokine production. J Virol 76: 4688–4698.
5. GanemD (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 1: 273–296.
6. SchulzTF (2006) The pleiotropic effects of Kaposi's sarcoma herpesvirus. J Pathol 208: 187–198.
7. SaidJW, TasakaT, TakeuchiS, AsouH, de VosS, et al. (1996) Primary effusion lymphoma in women: report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood 88: 3124–3128.
8. SoulierJ, GrolletL, OksenhendlerE, CacoubP, Cazals-HatemD, et al. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86: 1276–1280.
9. EnsoliB, SturzlM (1998) Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev 9: 63–83.
10. GrossmannC, PodgrabinskaS, SkobeM, GanemD (2006) Activation of NF-kappaB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J Virol 80: 7179–7185.
11. PyakurelP, PakF, MwakigonjaAR, KaayaE, HeidenT, et al. (2006) Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development. Int J Cancer 119: 1262–1267.
12. DupinN, FisherC, KellamP, AriadS, TulliezM, et al. (1999) Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96: 4546–4551.
13. RosanoL, SpinellaF, Di CastroV, NicotraMR, AlbiniA, et al. (2003) Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol 163: 753–762.
14. PantanowitzL, DezubeBJ, Hernandez-BarrantesS, TahanSR, DabbousMK (2006) Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol 33: 793–798.
15. BlankaertD, SimonartT, Van VoorenJP, ParentD, LiesnardC, et al. (1998) Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 18: 203–209.
16. QianLW, XieJ, YeF, GaoSJ (2007) Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol 81: 7001–7010.
17. FingletonB, MatrisianLM (2001) Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Curr Opin Oncol 13: 368–373.
18. DeryuginaEI, QuigleyJP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9–34.
19. SimmonsDL, BottingRM, HlaT (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387–437.
20. Sharma-WaliaN, PaulAG, BotteroV, SadagopanS, VeettilMV, et al. (2010) Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog 6: e1000777.
21. LuH, OuyangW, HuangC (2006) Inflammation, a key event in cancer development. Mol Cancer Res 4: 221–233.
22. SalesKJ, KatzAA, HowardB, SoetersRP, MillarRP, et al. (2002) Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62: 424–432.
23. NaranattPP, KrishnanHH, SvojanovskySR, BloomerC, MathurS, et al. (2004) Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res 64: 72–84.
24. Sharma-WaliaN, RaghuH, SadagopanS, SivakumarR, VeettilMV, et al. (2006) Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol 80: 6534–6552.
25. BrinkmannMM, PietrekM, Dittrich-BreiholzO, KrachtM, SchulzTF (2007) Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. J Virol 81: 42–58.
26. ShelbyBD, LaMarcaHL, McFerrinHE, NelsonAB, LaskyJA, et al. (2007) Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells. Virol J 4: 87.
27. GanemD (2010) KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 120: 939–949.
28. GiraldoG, BethE, HuangES (1980) Kaposi's sarcoma and its relationship to cytomegalovirus (CMNV). III. CMV DNA and CMV early antigens in Kaposi's sarcoma. Int J Cancer 26: 23–29.
29. MoorePS, ChangY (2001) Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 356: 499–516.
30. NicholasJ (2005) Human gammaherpesvirus cytokines and chemokine receptors. J Interferon Cytokine Res 25: 373–383.
31. GreeneW, KuhneK, YeF, ChenJ, ZhouF, et al. (2007) Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res 133: 69–127.
32. MartinJN, OsmondDH (1999) Kaposi's sarcoma-associated herpesvirus and sexual transmission of cancer risk. Curr Opin Oncol 11: 508–515.
33. GrundhoffA, GanemD (2004) Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113: 124–136.
34. AuWW, CallahamMF, WorkmanML, HubermanE (1983) Double minute chromatin bodies and other chromosome alterations in human myeloid HL-60 leukemia cells susceptible or resistant to induction of differentiation by phorbol-12-myristate-13-acetate. Cancer Res 43: 5873–5878.
35. KitzisA, TichonickyL, DeferN, KruhJ (1980) Effect of sodium butyrate on chromatin structure. Biochem Biophys Res Commun 93: 833–841.
36. LuF, ZhouJ, WiedmerA, MaddenK, YuanY, et al. (2003) Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol 77: 11425–11435.
37. LukacDM, RenneR, KirshnerJR, GanemD (1998) Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252: 304–312.
38. DeutschE, CohenA, KazimirskyG, DovratS, RubinfeldH, et al. (2004) Role of protein kinase C delta in reactivation of Kaposi's sarcoma-associated herpesvirus. J Virol 78: 10187–10192.
39. FordPW, BryanBA, DysonOF, WeidnerDA, ChintalgattuV, et al. (2006) Raf/MEK/ERK signalling triggers reactivation of Kaposi's sarcoma-associated herpesvirus latency. J Gen Virol 87: 1139–1144.
40. ChangH, DittmerDP, ShinYC, HongY, JungJU (2005) Role of Notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 79: 14371–14382.
41. LanK, MurakamiM, ChoudhuriT, KuppersDA, RobertsonES (2006) Intracellular-activated Notch1 can reactivate Kaposi's sarcoma-associated herpesvirus from latency. Virology 351: 393–403.
42. LiangY, ChangJ, LynchSJ, LukacDM, GanemD (2002) The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev 16: 1977–1989.
43. XieJ, AjibadeAO, YeF, KuhneK, GaoSJ (2008) Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 371: 139–154.
44. ChengF, Weidner-GlundeM, VarjosaloM, RainioEM, LehtonenA, et al. (2009) KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog 5: e1000324.
45. QinD, FengN, FanW, MaX, YanQ, et al. (2011) Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi's sarcoma-associated herpesvirus by herpes simplex virus type 1. BMC Microbiol 11: 240.
46. GregorySM, WestJA, DillonPJ, HilscherC, DittmerDP, et al. (2009) Toll-like receptor signaling controls reactivation of KSHV from latency. Proc Natl Acad Sci U S A 106: 11725–11730.
47. AouadiM, TeszGJ, NicoloroSM, WangM, ChouinardM, et al. (2009) Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458: 1180–1184.
48. BouzakriK, ZierathJR (2007) MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 282: 7783–7789.
49. CollinsCS, HongJ, SapinosoL, ZhouY, LiuZ, et al. (2006) A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 103: 3775–3780.
50. LiangJJ, WangH, RashidA, TanTH, HwangRF, et al. (2008) Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 14: 7043–7049.
51. LiuAW, CaiJ, ZhaoXL, JiangTH, HeTF, et al. (2011) ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 17: 710–720.
52. PuriV, VirbasiusJV, GuilhermeA, CzechMP (2008) RNAi screens reveal novel metabolic regulators: RIP140, MAP4k4 and the lipid droplet associated fat specific protein (FSP) 27. Acta Physiol (Oxf) 192: 103–115.
53. TeszGJ, GuilhermeA, GunturKV, HubbardAC, TangX, et al. (2007) Tumor necrosis factor alpha (TNFalpha) stimulates Map4k4 expression through TNFalpha receptor 1 signaling to c-Jun and activating transcription factor 2. J Biol Chem 282: 19302–19312.
54. TangX, GuilhermeA, ChakladarA, PowelkaAM, KondaS, et al. (2006) An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport. Proc Natl Acad Sci U S A 103: 2087–2092.
55. GunturKV, GuilhermeA, XueL, ChawlaA, CzechMP (2010) Map4k4 negatively regulates peroxisome proliferator-activated receptor (PPAR) gamma protein translation by suppressing the mammalian target of rapamycin (mTOR) signaling pathway in cultured adipocytes. J Biol Chem 285: 6595–6603.
56. CampbellTB, BorokM, WhiteIE, GudzaI, NdemeraB, et al. (2003) Relationship of Kaposi sarcoma (KS)-associated herpesvirus viremia and KS disease in Zimbabwe. Clin Infect Dis 36: 1144–1151.
57. HumphreyRW, O'BrienTR, NewcombFM, NishiharaH, WyvillKM, et al. (1996) Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Blood 88: 297–301.
58. PanH, XieJ, YeF, GaoSJ (2006) Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection. J Virol 80: 5371–5382.
59. JarviluomaA, OjalaPM (2006) Cell signaling pathways engaged by KSHV. Biochim Biophys Acta 1766: 140–158.
60. VieiraJ, O'HearnPM (2004) Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology 325: 225–240.
61. BriotD, Mace-AimeG, SubraF, RosselliF (2008) Aberrant activation of stress-response pathways leads to TNF-alpha oversecretion in Fanconi anemia. Blood 111: 1913–1923.
62. EdgellCJ, McDonaldCC, GrahamJB (1983) Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A 80: 3734–3737.
63. KaramanMW, HerrgardS, TreiberDK, GallantP, AtteridgeCE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127–132.
64. YaoZ, ZhouG, WangXS, BrownA, DienerK, et al. (1999) A novel human STE20-related protein kinase, HGK, that specifically activates the c-Jun N-terminal kinase signaling pathway. J Biol Chem 274: 2118–2125.
65. MackFA, PatelJH, BijuMP, HaaseVH, SimonMC (2005) Decreased growth of Vhl−/− fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol Cell Biol 25: 4565–4578.
66. ChatterjeeM, OsborneJ, BestettiG, ChangY, MoorePS (2002) Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 298: 1432–1435.
67. KedesDH, GanemD (1997) Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 99: 2082–2086.
68. BaumgartnerM, SillmanAL, BlackwoodEM, SrivastavaJ, MadsonN, et al. (2006) The Nck-interacting kinase phosphorylates ERM proteins for formation of lamellipodium by growth factors. Proc Natl Acad Sci U S A 103: 13391–13396.
69. SimonartT, DegraefC, MosselmansR, HermansP, Lunardi-IskandarY, et al. (2001) Early- and late-stage Kaposi's sarcoma-derived cells but not activated endothelial cells can invade de-epidermized dermis. J Invest Dermatol 116: 679–685.
70. AlkharsahKR, SinghVV, BoscoR, SantagS, GrundhoffA, et al. (2011) Deletion of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein, vFLIP, from the viral genome compromises the activation of STAT1-responsive cellular genes and spindle cell formation in endothelial cells. J Virol 85: 10375–10388.
71. BongiornoMR, DoukakiS, FerroG, AricoM (2010) Matrix metalloproteinases 2 and 9, and extracellular matrix in Kaposi's sarcoma. Dermatol Ther 23 Suppl 2: S33–36.
72. Meade-TollinLC, WayD, WitteMH (1999) Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem 101: 305–316.
73. YamamotoN, BryceNS, Metzler-NolteN, HambleyTW (2012) Effects of Enzymatic Activation on the Distribution of Fluorescently Tagged MMP-2 Cleavable Peptides in Cancer Cells and Spheroids. Bioconjug Chem [epub ahead of print].
74. Beeghly-FadielA, LongJR, GaoYT, LiC, QuS, et al. (2008) Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality. Cancer Res 68: 6453–6459.
75. ShiomiT, OkadaY (2003) MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 22: 145–152.
76. LeeSK, HanYM, YunJ, LeeCW, ShinDS, et al. (2012) Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells. Int J Cancer 131: E190–203.
77. WangFQ, SmicunY, CalluzzoN, FishmanDA (2006) Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion. Mol Cancer Res 4: 831–841.
78. YueW, SunQ, LandreneauR, WuC, SiegfriedJM, et al. (2009) Fibulin-5 suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 expression. Cancer Res 69: 6339–6346.
79. Ala-AhoR, JohanssonN, BakerAH, KahariVM (2002) Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. Int J Cancer 97: 283–289.
80. FournierT, FadokV, HensonPM (1997) Tumor necrosis factor-alpha inversely regulates prostaglandin D2 and prostaglandin E2 production in murine macrophages. Synergistic action of cyclic AMP on cyclooxygenase-2 expression and prostaglandin E2 synthesis. J Biol Chem 272: 31065–31072.
81. GreenhoughA, SmarttHJ, MooreAE, RobertsHR, WilliamsAC, et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377–386.
82. QiuMH, QianYM, ZhaoXL, WangSM, FengXJ, et al. (2012) Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract 208: 541–548.
83. KatanoH, SatoY, KurataT, MoriS, SataT (2000) Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 269: 335–344.
84. ChengF, PekkonenP, LaurinaviciusS, SugiyamaN, HendersonS, et al. (2011) KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell Host Microbe 10: 577–590.
85. FonsatoV, ButtiglieriS, DeregibusMC, BussolatiB, CaselliE, et al. (2008) PAX2 expression by HHV-8-infected endothelial cells induced a proangiogenic and proinvasive phenotype. Blood 111: 2806–2815.
86. SadagopanS, Sharma-WaliaN, VeettilMV, BotteroV, LevineR, et al. (2009) Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. J Virol 83: 3342–3364.
87. DillonPJ, GregorySM, TamburroK, SandersMK, JohnsonGL, et al. (2013) Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host Microbe 13: 204–214.
88. NaranattPP, AkulaSM, ZienCA, KrishnanHH, ChandranB (2003) Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity. J Virol 77: 1524–1539.
89. SodhiA, MontanerS, PatelV, ZoharM, BaisC, et al. (2000) The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 60: 4873–4880.
90. GallagherTF, SeibelGL, KassisS, LaydonJT, BlumenthalMJ, et al. (1997) Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 5: 49–64.
91. JacksonJR, BologneseB, HillegassL, KassisS, AdamsJ, et al. (1998) Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 284: 687–692.
92. LeeJC, KassisS, KumarS, BadgerA, AdamsJL (1999) p38 mitogen-activated protein kinase inhibitors–mechanisms and therapeutic potentials. Pharmacol Ther 82: 389–397.
93. BoehmJC, BowerMJ, GallagherTF, KassisS, JohnsonSR, et al. (2001) Phenoxypyrimidine inhibitors of p38alpha kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles. Bioorg Med Chem Lett 11: 1123–1126.
94. EdrakiN, HemmateenejadB, MiriR, KhoshneviszadeM (2007) QSAR study of Phenoxypyrimidine Derivatives as Potent Inhibitors of p38 Kinase using different chemometric tools. Chem Biol Drug Des 70: 530–539.
95. FabianMA, BiggsWH3rd, TreiberDK, AtteridgeCE, AzimioaraMD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329–336.
96. PouliotM, BaillargeonJ, LeeJC, ClelandLG, JamesMJ (1997) Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. J Immunol 158: 4930–4937.
97. LeeJC, BadgerAM, GriswoldDE, DunningtonD, TrunehA, et al. (1993) Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann N Y Acad Sci 696: 149–170.
98. CuendaA, RouseJ, DozaYN, MeierR, CohenP, et al. (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229–233.
99. ManningAM, DavisRJ (2003) Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2: 554–565.
100. RinconM, DavisRJ (2009) Regulation of the immune response by stress-activated protein kinases. Immunol Rev 228: 212–224.
101. XieJ, PanH, YooS, GaoSJ (2005) Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways. J Virol 79: 15027–15037.
102. AnJ, SunY, SunR, RettigMB (2003) Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene 22: 3371–3385.
103. Paulose-MurphyM, HaNK, XiangC, ChenY, GillimL, et al. (2001) Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol 75: 4843–4853.
104. KangJG, MajerciakV, UldrickTS, WangX, KruhlakM, et al. (2011) Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. J Pathol 225: 378–389.
105. NindlI, DangC, ForschnerT, KubanRJ, MeyerT, et al. (2006) Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer 5: 30.
106. HanSX, ZhuQ, MaJL, ZhaoJ, HuangC, et al. (2010) Lowered HGK expression inhibits cell invasion and adhesion in hepatocellular carcinoma cell line HepG2. World J Gastroenterol 16: 4541–4548.
107. AmbrusJL, StollHL, KleinEA, KarakousisCP, StadlerS (1992) Increased prostaglandin E2 and cAMP phosphodiesterase levels in Kaposi's sarcoma–a virus against host defense mechanism. Res Commun Chem Pathol Pharmacol 78: 249–252.
108. GaoSJ, DengJH, ZhouFC (2003) Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells. J Virol 77: 9738–9749.
109. ZhuH, CongJP, YuD, BresnahanWA, ShenkTE (2002) Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci U S A 99: 3932–3937.
110. RottD, ZhuJ, BurnettMS, ZhouYF, Zalles-GanleyA, et al. (2003) Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 41: 1812–1819.
111. KlineJN, HunninghakeGM, HeB, MonickMM, HunninghakeGW (1998) Synergistic activation of the human cytomegalovirus major immediate early promoter by prostaglandin E2 and cytokines. Exp Lung Res 24: 3–14.
112. JanelleME, GravelA, GosselinJ, TremblayMJ, FlamandL (2002) Activation of monocyte cyclooxygenase-2 gene expression by human herpesvirus 6. Role for cyclic AMP-responsive element-binding protein and activator protein-1. J Biol Chem 277: 30665–30674.
113. SymensmaTL, Martinez-GuzmanD, JiaQ, BortzE, WuTT, et al. (2003) COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression. J Virol 77: 12753–12763.
114. KhyattiM, MenezesJ (1990) The effect of indomethacin, prostaglandin E2 and interferon on the multiplication of herpes simplex virus type 1 in human lymphoid cells. Antiviral Res 14: 161–172.
115. GatanagaT, HwangCD, KohrW, CappucciniF, LucciJA3rd, et al. (1990) Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A 87: 8781–8784.
116. Ben-AvP, CroffordLJ, WilderRL, HlaT (1995) Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 372: 83–87.
117. TsujiiM, KawanoS, TsujiS, SawaokaH, HoriM, et al. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705–716.
118. ShengH, ShaoJ, DuboisRN (2001) K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res 61: 2670–2675.
119. HuKQ, YuCH, MineyamaY, McCrackenJD, HillebrandDJ, et al. (2003) Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. Int J Oncol 22: 757–763.
120. HarrisRE (2007) Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 42: 93–126.
121. TjiuJW, ChenJS, ShunCT, LinSJ, LiaoYH, et al. (2009) Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol 129: 1016–1025.
122. LeglerDF, BrucknerM, Uetz-von AllmenE, KrauseP (2010) Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol 42: 198–201.
123. RaHJ, Harju-BakerS, ZhangF, LinhardtRJ, WilsonCL, et al. (2009) Control of promatrilysin (MMP7) activation and substrate-specific activity by sulfated glycosaminoglycans. J Biol Chem 284: 27924–27932.
124. KnauperV, WillH, Lopez-OtinC, SmithB, AtkinsonSJ, et al. (1996) Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 271: 17124–17131.
125. NagaseH, WoessnerJFJr (1999) Matrix metalloproteinases. J Biol Chem 274: 21491–21494.
126. YanC, BoydDD (2007) Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211: 19–26.
127. OzanneBW, SpenceHJ, McGarryLC, HenniganRF (2007) Transcription factors control invasion: AP-1 the first among equals. Oncogene 26: 1–10.
128. LiaciniA, SylvesterJ, LiWQ, HuangW, DehnadeF, et al. (2003) Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 288: 208–217.
129. MengsholJA, VincentiMP, BrinckerhoffCE (2001) IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 29: 4361–4372.
130. WisithphromK, MurrayPE, WindsorLJ (2006) Interleukin-1 alpha alters the expression of matrix metalloproteinases and collagen degradation by pulp fibroblasts. J Endod 32: 186–192.
131. WestermarckJ, KahariVM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781–792.
132. JaffeEA, NachmanRL, BeckerCG, MinickCR (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745–2756.
133. MayT, ButuevaM, BantnerS, MarkusicD, SeppenJ, et al. (2010) Synthetic gene regulation circuits for control of cell expansion. Tissue Eng Part A 16: 441–452.
134. MilliganS, RobinsonM, O'DonnellE, BlackbournDJ (2004) Inflammatory cytokines inhibit Kaposi's sarcoma-associated herpesvirus lytic gene transcription in in vitro-infected endothelial cells. J Virol 78: 2591–2596.
135. XuY, AuCoinDP, HueteAR, CeiSA, HansonLJ, et al. (2005) A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. J Virol 79: 3479–3487.
136. KatiS, TsaoEH, GuntherT, Weidner-GlundeM, RothamelT, et al. (2013) Activation of the B Cell Antigen Receptor Triggers Reactivation of Latent Kaposi's Sarcoma-Associated Herpesvirus in B Cells. J Virol 87: 8004–8016.
137. CarpenterAE, JonesTR, LamprechtMR, ClarkeC, KangIH, et al. (2006) CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7: R100.
138. OtsuN (1979) Threshold Selection Method from Gray-Level Histograms. Ieee Transactions on Systems Man and Cybernetics 9: 62–66.